Kevin Salim
LightNews LightNews
kevinsalim.bsky.social
Kevin Salim
@kevinsalim.bsky.social
1.7K followers 1.2K following 3 posts
Graduate Student | Levings Lab | BC Children’s Hospital Research Institute | Regulatory T Cells | He/him 🏳️‍🌈
Posts Replies Media Videos
Reposted by Kevin Salim
labwaggoner.bsky.social
Engineered β cells with a mutant CD155 help evade immune attack, offering a promising therapeutic approach for type 1 diabetes @bruskolab.bsky.social
www.science.org/doi/10.1126/...
Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes
Engineered β cells with a mutant CD155 help evade immune attack, offering a promising therapeutic approach for type 1 diabetes.
www.science.org
November 7, 2025 at 9:30 PM
Reposted by Kevin Salim
nictitate.bsky.social
Although things could always be better, it's great to see the government continuing to support research in this environment...a rising tide lifts all boats.
November 5, 2025 at 2:07 PM
Reposted by Kevin Salim
focisimmunology.bsky.social
The FOCIS 2026 Scientific Program Committee has curated an exciting & dynamic program, featuring 4 keynote speakers and cutting-edge sessions in immunology. 🔬

Learn More: 🔗 zurl.co/P98Ja

#FOCIS2026 #immunology #science
November 5, 2025 at 4:41 PM
Reposted by Kevin Salim
scienceinvancouver.com
New data from Christine Wardell and the Levings lab at UBC and @bcchresearch.bsky.social has demonstrated that A2-CAR Treg cells have potential therapeutic use to simultaneously control both allo- and #autoimmunity in islet transplantation.

Check it the paper: https://bit.ly/4nq3SIg
October 28, 2025 at 11:39 PM
Reposted by Kevin Salim
stemcellnetwork.ca
SCN is offering trainee travel awards to attend MASSIV 1.0: The Meeting for Advanced Synthetic Biology and Systems Bioengineering.

Don’t miss this chance to connect with leading experts in #SyntheticBiology, #bioengineering, and #RegenerativeMedicine. 🤝

🔗 stemcellnetwork.ca/training/wor...
MASSIV 1.0:
October 29, 2025 at 12:46 PM
Reposted by Kevin Salim
stemcellnetwork.ca
(1/3) 📢 SCN is pleased to announce the release of our 'What We Heard' report, Preparing Canada’s Health System for Regenerative Medicines and Advanced Therapeutics: Cell Therapies for Type 1 Diabetes.

🔗 Read the report: stemcellnetwork.ca/wp-content/u...
Preparing Canada’s Health System for Regenerative Medicines and Advanced Therapeutics: Cell Therapies for Type 1 Diabetes
October 27, 2025 at 6:00 PM
Reposted by Kevin Salim
chrysothemisbrown.bsky.social
Excited to share our review on Thetis cells and dendritic cells, and their roles in mucosal immunity and tolerance @natimmunol.nature.com rdcu.be/eLtB1
Antigen-presenting cells as arbiters of mucosal tolerance and immunity
Nature Immunology - Brown and colleagues review the heterogeneity of mucosal antigen-presenting cells that orchestrate T cell immunity to intestinal antigens.
urldefense.com
October 17, 2025 at 12:22 PM
Reposted by Kevin Salim
labwaggoner.bsky.social
HLA matching or CRISPR editing HLA-I/II enables engraftment & function of allo human Treg therapy in a humanized mouse transplantation model @natcomms.nature.com @dlwagner.bsky.social @bcmhouston.bsky.social
www.nature.com/articles/s41...
October 13, 2025 at 5:39 PM
Reposted by Kevin Salim
labwaggoner.bsky.social
Temporal and context-dependent requirements for the transcription factor Foxp3 expression in regulatory T cells @natimmunol.nature.com @yuripritykin.bsky.social Rudensky @princetonupress.bsky.social @mskcancercenter.bsky.social www.nature.com/articles/s41...
October 8, 2025 at 5:17 PM
Reposted by Kevin Salim
nephjc.bsky.social
Chimerism might just be the 🔑 to immune tolerance and ending the need for immunosuppression 🚫💊after transplantation 🫘.
Join the discussion 9/30/25 at 9 pm EST on Bluesky #NephSky #MedSky #NephJC
www.nephjc.com/news/chimera-tolerance-njqe334
Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression? — NephJC
This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.
www.nephjc.com
September 29, 2025 at 1:56 AM
Reposted by Kevin Salim
labliston.bsky.social
For our #flowcytometry peeps, would you like to have a single fix/perm protocol that is optimised for everything? One that preserves fluorophores while allowing simultaneous TF and cytokine staining? How about 100-fold cheaper?

You got it:
currentprotocols.onlinelibrary.wiley.com/doi/10.1002/...
currentprotocols.onlinelibrary.wiley.com
September 19, 2025 at 2:39 PM
Reposted by Kevin Salim
jraylab.bsky.social
Excited to finally present the lab's latest work in defining candidate causal genetic variants that drive autoimmune diseases and their effects on primary human T cell expression and function! www.nature.com/articles/s41...
Genetic and epigenetic screens in primary human T cells link candidate causal autoimmune variants to T cell networks - Nature Genetics
Massively parallel reporter assay in primary human CD4+ T cells and bulk and single-cell CRISPR-interference screens identify candidate causal variants linked to autoimmune disease risk that modulate ...
www.nature.com
September 18, 2025 at 8:50 PM
Reposted by Kevin Salim
natrevendo.nature.com
ICYMI: New content online: Antigen-specific Treg cells induce infectious tolerance
Antigen-specific Treg cells induce infectious tolerance
Nature Reviews Endocrinology, Published online: 11 September 2025; doi:10.1038/s41574-025-01182-0Antigen-specific Treg cells induce infectious tolerance
www.nature.com
September 13, 2025 at 10:02 AM
Reposted by Kevin Salim
dlwagnerlabs.bsky.social
Lab History pt. 5 (2025)

What is the best Knock-in strategy to make CAR-Tregs??

our answer is published in Molecular Therapy 🔗
www.cell.com/molecular-th...
September 18, 2025 at 12:38 AM
Reposted by Kevin Salim
sarahcrome.bsky.social
This meeting has always been a highlight for the ILC community, and Vancouver 2026 already features an exciting lineup of confirmed speakers.

🔗 ilc6vancouver.com

#ILC6 #Immunology #InnateLymphoidCells, #ILC, #ILC2, #ILC3, #NKcells, #ILC1 #Immunosky
September 9, 2025 at 6:24 PM
Reposted by Kevin Salim
sarahcrome.bsky.social
Thrilled to share that I’ve officially started my new role as a Senior Scientist in the Terry Fox Laboratory at the BC Cancer Research Centre. I’m excited to join this inspiring community, build new collaborations, and explore bold ideas together.
September 2, 2025 at 5:07 PM
Reposted by Kevin Salim
natrevdrugdiscov.nature.com
Therapeutic strategies aiming to enhance or inhibit regulatory T cell activity are being investigated in diseases including allergy, autoimmune disorders and cancer - find out more in this review by Megan Levings et al.
www.nature.com/articles/s41...
rdcu.be/eDrL0
Harnessing the biology of regulatory T cells to treat disease - Nature Reviews Drug Discovery
Regulatory T cells keep the immune system in check to maintain homeostasis and restrain inflammation. This Review discusses strategies to harness these cells therapeutically for autoimmunity, transpla...
www.nature.com
September 2, 2025 at 3:17 PM
Reposted by Kevin Salim
ckarampelias.bsky.social
Check out the latest manuscript from the @heikolickert.bsky.social lab on generating a defined stem-cell derived islet product for transplantation.
A thorough characterization of the system particularly by our star PhD students Nike and Nicole! #PancSky
www.biorxiv.org/content/10.1...
Endocrine-enriched stem cell-derived islets improve long-term safety in vivo
Fully differentiated stem cell-derived islets (SC-islets) are proven to normalise blood glucose in type 1 diabetic patients. However, the presence of off-target cell types and the immature SC-islet fu...
www.biorxiv.org
August 24, 2025 at 4:19 PM
Reposted by Kevin Salim
science.org
A hemisphere-spanning study defines synchronicity and climatic influence on dengue in the Americas, polymer-stabilized microparticles enable easy injection of commercial protein therapies, and more this week in #ScienceTranslationalMedicine. https://scim.ag/4lvOc5i
The cover depicts the presence of human-leukocyte antigen (HLA)-A2-specific chimeric antigen receptor (CAR) regulatory T cells (A2-CAR Tregs) expressing FOXP3 (yellow) and CD3 (red) as well as diabetogenic BDC2.5 T cells expressing vβ4 (cyan) and CD3 in and around transplanted HLA-A2+ NOD. Rag1-/- islets in the eye of an immunodeficient mouse.
August 20, 2025 at 9:00 PM
Reposted by Kevin Salim
mklevings.bsky.social
So excited that our paper on CAR Tregs and infectious tolerance made the cover of Science Translational Medicine today! @science.org
August 20, 2025 at 9:51 PM
Reposted by Kevin Salim
labwaggoner.bsky.social
HLA-A2–specific chimeric antigen receptor–engineered regulatory T cells tolerize diabetogenic T cells and prevent autoimmune diabetes in mice
www.science.org/doi/10.1126/... @mklevings.bsky.social
August 20, 2025 at 8:57 PM
Reposted by Kevin Salim
cp-cellrepmed.bsky.social
Online now: TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation
TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation
Tuomela et al. report that TYK2 inhibition does not affect human Treg induction from naive CD4+ T cells, promotes Treg differentiation in lamina propria-derived T cells, and increases blood-derived Treg stability and function. In contrast, JAK inhibition strongly impairs Treg function and phenotype.
dlvr.it
August 19, 2025 at 7:19 PM
Reposted by Kevin Salim
labwaggoner.bsky.social
TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation
@cp-cellrepmed.bsky.social
@mklevings.bsky.social
cell.com/cell-reports...
August 19, 2025 at 8:30 PM
Reposted by Kevin Salim
labwaggoner.bsky.social
@biorxivpreprint.bsky.social High-affinity CD155 expression enhances immune evasion of Stem cell-derived β-cells, improving their potential for restorative therapy in type 1 diabetes @bruskolab.bsky.social ‪@mebrown4.bsky.social‬
www.biorxiv.org/content/10.1...
August 16, 2025 at 4:23 AM
Reposted by Kevin Salim
drleoferreira.bsky.social
A new engineered regulatory T cell is born. Chimeric anti-HLA receptor regulatory T cells (CHAR Tregs) inhibit antibody production by B cells from HLA sensitized transplant patients, offering a precise approach to tackle antibody-mediated organ rejection.
www.frontiersin.org/journals/imm...
August 16, 2025 at 1:49 PM